EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain
This Spanish real-world data analysis echoes previous findings and highlights unmet needs, including the proportion of patients not receiving systemic treatment and the limited progression to subsequent lines of therapy, hampering access to new effective treatments.
Authors
- Rebeca Fernández Rodríguez
- M. Arruti Ibarbia
- T. de Portugal Fernández del Rivero
- Ignacio Durán (ORCID: https://orcid.org/0000-0001-8571-7163)
- Nuria Laínez Milagro
- Carlos Álvarez-Fernández (ORCID: https://orcid.org/0000-0002-2500-074X)
- M. Martínez Kareaga (ORCID: https://orcid.org/0000-0002-2599-5791)
- E. Pujol Obis
- R. Sánchez-Escribano
- N. Sagastibeltza
- M. Pumares González
- I. Gil Arnaiz
- A. Pereira-Elorrieta
- A. Lacalle Emborujo
- J.A. Verdún Aguilar
Institutions
- Zamorano Pan-American Agricultural School (HN)
- Clinic IMQ Zorrotzaurre (ES)
- Marqués de Valdecilla University Hospital (ES)
- Hospital Txagorritxu (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario de Burgos (ES)
- Hospital de Galdakao (ES)
- Hospital Universitario Reina Sofía (ES)
- Hospital Universitario Central de Asturias (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Hospital San Pedro (ES)
- Donostiako Unibertsitate Ospitalea (ES)
- Universidad de Zamora (MX)
- Hospital Clínico Universitario de Valladolid (ES)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100063
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Astellas Pharma